David OjciusLeveraging intratumoral probiotics for pancreatic cancer #immunotherapy via xenophagy.
#probiotic #microbiology #immunology
https://www.cell.com/cell-host-microbe/abstract/S1931-3128(26)00078-8
David UsharauliCatch-bond interactions are not easy to grasp compared to affinity and specificity. How are they measured, and is the approach reproducible?
GastroAGI🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?
⚠️ Promising data, but guidelines still need phase III confirmation
#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd
Hans-Cees 🌳🌳🤢🦋🐈🐈🍋🍋🐝🐜@xs4me2 Wetenschappers laten deze week zien dat de gezondheid van dit orgaan, ook wel thymus genoemd, verband houdt met levensduur, veroudering, risico op hart- en vaatziekten en kanker
Echte ontdekkings wetenschap waarbij #ai nuttig is ingezet bij een deel van de studie
#kanker #Immunotherapy
neat_newsIn a small study with 12 patients using immunotherapy with a new antibody injected directly into tumors meant for 6 patients that their tumors shrank and for 2 that they went in complete remission. See http://www.neat-news.com/3551.php. #cancer #immunotherapy
Orbit News HubMIIP Protein Blocks Colorectal Cancer Via Control of Immune Response
https://orbitnewshub.com/miip-protein-blocks-colorectal-cancer-via-control-of-immune-response/
#ColorectalCancer #MedicalResearch #Immunotherapy #OrbitNewsHub #HealthNews #CancerResearch
halama_immunoNew publication on the role of #macrophages in shaping the tumor #microenvironment in #cancer ... leading to the exploration of #adipose tissue and it's impact on #innateimmunity and #adaptiveimmunity in #ovariancancer to the point where resistancr to #immunotherapy is observed. These findings are then put into action for patient stratification, showing the utility in #radiology and #medicaloncology and #oncology #Science #medicine #immunology
Howard Smith MD, AMLaser-Aided Immunotherapy For Brain Cancer. Adding a laser procedure dramatically improves the results of immunotherapy for one of the deadliest brain cancers. #laser #immunotherapy #astrocytoma #cancer
https://www.instagram.com/p/DVt_oDBiVAO/
https://www.instagram.com/p/DVt_oDBiVAO/
Howard G. Smith MD, AM on Instagram: "Laser-Aided Immunotherapy For Brain Cancer Adding a laser procedure dramatically improves the results of immunotherapy for one of the deadliest brain cancers. Neuro-oncologists at USC report this development in the journal Nature Communications. In this Phase 1/2 clinical trial, 45 patients with recurrent astrocytoma were randomized to receive either laser interstitial thermal therapy (LITT) that destroys tumor tissue and opens the blood-brain barrier plus the immunotherapy with the drug pembrolizumab immunotherapy or standard care, surgery, followed by the immunotherapy. The results are striking: nearly 50% of patients in the LITT group were alive at 18 months, compared with 0% in the standard-treatment group. In addition, more than one-third of LITT-treated patients survived beyond three years, compared to a typical 4–5 month survival seen with surgery and immunotherapy. The addition of of LITT, adding laser therapy to immunotherapy, is a potential game-changing approach. These results are early and require confirmation in larger trials, they offer real hope in a disease with limited therapeutic options and generally poor outcomes. https://doi.org/10.1038/s41467-026-69522-w https://www.news-medical.net/news/20260226/Innovative-laser-procedure-offers-new-hope-for-recurrent-brain-tumors.aspx #laser #immunotherapy #astrocytoma #cancer"
0 likes, 0 comments - drhowardsmithreports on March 10, 2026: "Laser-Aided Immunotherapy For Brain Cancer Adding a laser procedure dramatically improves the results of immunotherapy for one of the deadliest brain cancers. Neuro-oncologists at USC report this development in the journal Nature Communications. In this Phase 1/2 clinical trial, 45 patients with recurrent astrocytoma were randomized to receive either laser interstitial thermal therapy (LITT) that destroys tumor tissue and opens the blood-brain barrier plus the immunotherapy with the drug pembrolizumab immunotherapy or standard care, surgery, followed by the immunotherapy. The results are striking: nearly 50% of patients in the LITT group were alive at 18 months, compared with 0% in the standard-treatment group. In addition, more than one-third of LITT-treated patients survived beyond three years, compared to a typical 4–5 month survival seen with surgery and immunotherapy. The addition of of LITT, adding laser therapy to immunotherapy, is a potential game-changing approach. These results are early and require confirmation in larger trials, they offer real hope in a disease with limited therapeutic options and generally poor outcomes. https://doi.org/10.1038/s41467-026-69522-w https://www.news-medical.net/news/20260226/Innovative-laser-procedure-offers-new-hope-for-recurrent-brain-tumors.aspx #laser #immunotherapy #astrocytoma #cancer".
Cindymy Cancer Team is AWESOME but when patients are sometimes advised to "eat whatever U want" ~ I DISAGREE & Don't comply! My ailing body Needs food that NOURISHES & That certainly isn't going to be a steady supply of junk food that I *want* (occasional treats are ok😋).
Oncology doctors are experts on mainstream medical care like #chemotherapy #radiation #immunotherapy , Not #nutrition
They prescribe the most helpful #cancertreatment possible while I manage my grocery list, pantry & kitchen stove😉
Oncology doctors are experts on mainstream medical care like #chemotherapy #radiation #immunotherapy , Not #nutrition
They prescribe the most helpful #cancertreatment possible while I manage my grocery list, pantry & kitchen stove😉
Summarized Science🦠 Melanoma - Feb 2026
• Personalized mRNA vaccine shows durable reduction in melanoma recurrence
• HOXD13 regulates angiogenesis and immune evasion in melanoma
• Pepyrus boosts sensitivity in HLA-bound neoantigen discovery
• SITC defines consensus criteria for ICI resistance
• Vibostolimab adds no benefit over pembrolizumab alone in melanoma
• Pathologic response assessment shows high reproducibility across tumor types
